Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 3/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 3/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MAP2 | P11137 | 1/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28535010 | 0.94 | AKR1C2 (0.53) | AKR1C2AKR1C1ALDH1A1ALOX15DHODH | |
| SCHEMBL505832 | 0.83 | AKR1C2 (0.61) | AKR1C2AKR1C1ALDH1A1DHODHEGFR | |
| SCHEMBL10029672 | 0.83 | AKR1C2 (0.56) | AKR1C2AKR1C1ALDH1A1DHODHEGFR | |
| SCHEMBL26352578 | 0.80 | AKR1C2 (0.53) | AKR1C2AKR1C1DHODHEGFRKDM4E | |
| SCHEMBL29129812 | 0.78 | AKR1C2 (0.50) | AKR1C2AKR1C1ALDH1A1ALOX15EGFR | |
| SCHEMBL4864533 | 0.77 | ALDH1A1 (0.57) | AKR1C2AKR1C1ALDH1A1ALOX15DHODH | |
| SCHEMBL4603812 | 0.77 | ACP3 (0.42) | AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL30638614 | 0.76 | DHODH (0.49) | AKR1C2AKR1C1ALDH1A1DHODHEGFR | |
| Biphenyl SCHEMBL2838517 | 0.73 | AKR1C2 (0.50) | AKR1C2AKR1C1ALDH1A1DHODHKMO | |
| SCHEMBL105255 | 0.73 | CES2 (0.64) | ALDH1A1ALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233889-B1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| CN-107257803-B | Polymyxin antibacterial agents for the treatment of bacterial infections | 上海盟科药业股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3233889-A2 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | Micurx Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| CN-107257803-A | Polymyxins antiseptic for treating bacterium infection | 盟科医药技术公司（开曼群岛） | 2017-10-17 | — | — | CN | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| WO-2016100578-A2 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | AKR1C2 3313/4885AKR1C1 3152/4885ALDH1A1 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.